Pathophysiology of Haemostasis and Thrombosis

 

Oral Anticoagulant Therapy: Efficacy, Safety and the Low-Dose Controversy

Coccheri S. · Palareti G. · Cosmi B.

Author affiliations

Chair and Department of Angiology and Blood Coagulation, University Hospital S. Orsola, Bologna, Italy

Keywords: Oral anticoagulantsWarfarinVenous thromboembolismAtrial fibrillationAcute coronary syndromes

Related Articles for ""
Haemostasis 1999;29:150–165
https://doi.org/10.1159/000022495

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 12, 2000
Issue release date: December 1999

Number of Print Pages: 16
Number of Figures: 0
Number of Tables: 0

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: https://www.karger.com/PHT

Abstract

The issue of optimal duration of oral anticoagulant therapy after a first episode of venous thromboembolism is still unresolved. However, recent data suggest that short (6 weeks to 3 months), intermediate (3– 6 months) or indefinite-term anticoagulant therapy should be adopted on the basis of the classification of patients into low-, intermediate- and high-recurrence-risk groups, respectively. Oral anticoagulants have been shown to effectively prevent cardioembolic stroke in nonvalvular atrial fibrillation. Recent data seem to suggest that their safety can be ameliorated with adequate risk stratification on the basis of clinical and echocardiographic features. After unstable angina and non-Q-wave myocardial infarction, oral anticoagulant therapy (INR range 2–3) combined with aspirin has been shown to be advantageous over aspirin alone, although at the cost of a slight increase in bleeding. Bleeding complications are major drawbacks of oral anticoagulant therapy thus limiting their generalized adoption in recognized indications. To sharply reduce the bleeding risk and need of laboratory control, the low- or fixed-dose oral anticoagulant approach has been evaluated. In primary prevention and in low or low-to-moderate thrombotic risk, minidose warfarin treatment has been shown to be advantageous. In secondary prevention, and in patients at high risk for recurrent venous or arterial thrombotic events, standard range (INR 2–3) or higher level of anticoagulation is needed.

© 1999 S. Karger AG, Basel



Related Articles:

References

  1. Hull R, Raskob G, Pineo G, et al: A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl Med 1993;329:1370–1376.
    External Resources
  2. Schulman S, Rhedin AS, Lindmarker P, et al: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661.
    External Resources
  3. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393–398.
    External Resources
  4. Coccheri S, Palareti G: La terapia anticoagulante orale negli anni 90. Aspetti fisiopatologici, clinici, sociali. Atti del 97° Congresso della Scietà Italiana di Medicina Interna, Venice, October 1996. Roma, Pozzi, 1996, vol 1, pp 223–261.
  5. Barnett HSM, Eliciszin M, Meldrum ME: Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238–248.
    External Resources
  6. European Atrial Fibrillation Trial (EAFT) Study Group: Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and a recent ischaemic attack or minor stroke. Lancet 1993;342:255–262.
    External Resources
  7. Stroke Prevention in Atrial Fibrillation Investigators: Stroke prevention in atrial fibrillation study: Final results. Circulation 1991;84:527–539.
    External Resources
  8. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449–1457.
    External Resources
  9. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236–241.
    External Resources
  10. Palareti G, Poggi M, Guazzaloca G, Savino A, Coccheri S: Assessment of mental ability in elderly anticoagulated patients: Its reduction is associated with a less satisfactory quality of treatment. Blood Coagul Fibrinolysis 1997;8:411–417.
    External Resources
  11. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633–638.
    External Resources
  12. Vermeer F, Langenberg M, Hellemons BS, et al: Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation: Results of the PATAF study (abstract). Eur Heart J 1998;19(suppl):154.
  13. Gullov AL, Koefoed BG, Petersen P, et al: Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin an Anticoagulation Study. Arch Intern Med 1998;158:1513–1521.
    External Resources
  14. Pengo V, Zasso A, Barberi F, et al: Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in non-rheumatic atrial fibrillation. Am J Cardiol 1998;82:433–437.
    External Resources
  15. Palareti G, Leali N, Coccheri S, et al: Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423–428.
    External Resources
  16. Palareti G, Manotti C, Dangelo A, et al: Thrombotic events during oral anticoagulant treatment: Results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost 1997;78:1438–1443.
    External Resources
  17. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989;i:175–179.
  18. Morocutti C, Amabile G, Fattapposta F, et al: Indobufen versus warfarin in the secondary prevention of major vascular events in non-rheumatic atrial fibrillation. Stroke 1997;28:1015–1021.
    External Resources
  19. Atrial Fibrillation Investigators: The efficacy of aspirin in patients with atrial fibrillation. Arch Intern Med 1997;157:1237–1240.
    External Resources
  20. Brass LM, Krumholz HM, Scinto JM, Radford M: Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382–2389.
    External Resources
  21. Sato Y, Honda Y, Kunoh H, Oizumi K: Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and non-rheumatic atrial fibrillation. Stroke 1997;28:2390–2394.
    External Resources
  22. Lip GYH: Thromboprophylaxis for atrial fibrillation. Lancet 1999;353:4–6.
    External Resources
  23. Atrial Fibrillation Investigators: Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med 1998;158:1316–1320.
    External Resources
  24. Jonker JJC, Vanbergen PFMM, van der Meer FJM, et al: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499–503.
    External Resources
  25. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al: Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994;89:81–88.
    External Resources
  26. Coumadin Aspirin Reinfarction Study (CARS) Investigators: Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389–396.
    External Resources
  27. Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153–162.
    External Resources
  28. Anand S, Yusuf S, Pogue J, et al: Long-term anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction – Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study Results. Circulation 1998;98:1064–1070.
    External Resources
  29. Pengo V, Barbero F, Banzato A, et al: A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prosthesis. Thromb Haemost 1997;77:839–844.
    External Resources
  30. Turpie AGG, Gent M, Laupacis A, et al: A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993;329:524–529.
    External Resources
  31. Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J: Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: A meta-analysis. Am Heart J 1995;130:547–552.
    External Resources
  32. Landefeld CS, Beyth RJ: Anticoagulant-related bleeding – clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315–328.
    External Resources
  33. Fihn SD, Mcdonell M, Martin D, et al: Risk factors for complications of chronic anticoagulation – A multicenter study. Ann Intern Med 1993;118:511–520.
    External Resources
  34. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144–152.
    External Resources
  35. Anonymous: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997;42:857–865.
    External Resources
  36. Scott PJW: Anticoagulant drugs in the elderly: The risks usually outweigh the benefits. Br Med J 1988;i:1261–1263.
  37. Kutner M, Nixon G, Silverstone F: Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991;151:1950–1953.
    External Resources
  38. Russmann S, Gohlke-Barwolf C, Jahnchen E, Trenk D, Roskmann H: Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. Eur J Clin Pharmacol 1997;52:31–35.
    External Resources
  39. Hylek EM, Singer DE: Risk factors for intracranial haemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897–902.
    External Resources
  40. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for haemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665–1670.
    External Resources
  41. Arnsten J, Gelfand J, Singer DE: Determinants of compliance with anticoagulation: A case-control study. Am J Med 1997;103:11–17.
    External Resources
  42. Lau HS, Beuning KS, Postmalim E, Kleinbeernink L. Deboer A, Porsius AJ: Non-compliance in elderly people: Evaluation of risk factors by longitudinal data analysis. Pharm World Sci 1996;18:63–68.
    External Resources
  43. Levine MN, Hirsh J, Landefeld S, Raskob G: Haemorrhagic complication of anticoagulant treatment. Chest 1992;102:352S–363S.
  44. Beyth RJ, Landefeld CS: Anticoagulants in older patients: A safety perspective. Drugs Aging 1995;6:45–54.
    External Resources
  45. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E: Bleeding complications in oral anticoagulant therapy – An analysis of risk factors. Arch Intern Med 1993;153:1557–1562.
    External Resources
  46. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144–152.
    External Resources
  47. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K: Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1,010 treatment years in 551 outpatients. J Intern Med 1991;229:351–355.
    External Resources
  48. Petitti DB, Strom BL, Melmon KL: Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989;42:759–764.
    External Resources
  49. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Phil D, Silverstein MD: Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725–733.
    External Resources
  50. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E: Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76:12–16.
    External Resources
  51. Fihn SD, Callahan CM, Martin DC, Mcdonell MB, Henikoff JG, White RH: The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970–979.
    External Resources
  52. Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:401–416.
  53. Hull R, Delmore T, Carter C, et al: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189–194.
    External Resources
  54. Saour JN, Sieck JO, Mamo LAR, Gallus AS: Trial of different intensities of anticoagulation in patients with prothetic heart valves. N Engl J Med 1990;322:428–432.
    External Resources
  55. Altman R, Rouvier J, Gurfinkel E, et al: Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427–431.
    External Resources
  56. De Takats G: Anticoagulant therapy in surgery. JAMA 1950;142:527–534.
  57. Gitel SN, Wessler S: Dose dependent antithrombotic effect of warfarin in rabbits. Blood 1983;61:435–438.
    External Resources
  58. Braun PJ, Szewczyk KM: Relationship between total prothrombin, native prothrombin and the international normalized ratio (INR). Thromb Haemost 1992;68:160–164.
    External Resources
  59. Poller L, McCallum PK, Thomson JM, et al: Reduction of factor VII coagulant activity (VIIc) a risk factor for ischemic heart disease, by fixed dose warfarin: A double blind cross-over study. Br Heart J 1990;63:231–233.
    External Resources
  60. Holm J, Berntorp E, Carlsson R, Erhardt L: Low dose warfarin decreases coagulability without affecting prothrombin complex activity. J Intern Med 1993;234:303–308.
    External Resources
  61. Falanga A, Levine MN, Consonni R, et al: The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost 1998;79:23–27.
    External Resources
  62. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB: Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309–1312.
  63. MacCallum PK, Thompson JM, Poller L: Effect of mini-dose warfarin on coagulation and fibrinolysis following major gynecological surgery. Thromb Haemost 1990;64:511–515.
    External Resources
  64. Fordyce MJF, Baker AS, Staddon GE: Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. BMJ 1991;303:219–220.
    External Resources
  65. Bern MM, Lokich JJ, Wallach SR, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423–428.
    External Resources
  66. Levine M, Hirsh J, Gent M, et al: Double-blind randomized trial of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886–889.
    External Resources
  67. Rosendaal FR: Anticoagulation: How low can one go? (letter). Lancet 1994;343:867–868.
    External Resources
  68. Feinberg WM, Cornell ES, Nightingale SD, et al: Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1997;28:1101–1106.
    External Resources
  69. Peverill RE, Harris G, Gelman J, Gan TE, Harper RW, Smolich JJ: Effect of warfarin on regional left atrial coagulation activity in mitral stenosis. Am J Cardiol 1997;79:339–343.
    External Resources
  70. Koefoed BG, Feddersen C, Gullov AL, Petersen P: Effect of minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation. Thromb Haemost 1997;77:845–848.
    External Resources
  71. The Medical Research Council’s General Practice Research Framework: Thrombosis prevention trial: Randomised trial of low intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233–241.
    External Resources
  72. Meade TW, Mellow S, Brozovic M, et al: Hemostatic function and ischemic heart disease: Principal results of the Northwich Park Heart Study. Lancet 1986;ii:533–537.
  73. Puddock V, Meade TW: Factor VII activity and ischemic heart disease: Fatal and non-fatal events. Q J M ed 1994;87:403–406.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 12, 2000
Issue release date: December 1999

Number of Print Pages: 16
Number of Figures: 0
Number of Tables: 0

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: https://www.karger.com/PHT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

1999, Vol.29, No. 2-3

December 1999

Article

Recommend This
TOP